Pfizer announced Monday that its coronavirus vaccine demonstrated more than 90% effectiveness and no serious bad reactions in trial results — an outcome that should enable the company to obtain an emergency authorization soon. Between the vaccine and the unveiling, also on Monday, of a Biden-led coronavirus task force, it seemed like the rare pandemic-era day in which the good news could compete with the tragic. But Pulitzer Prize–winning science writer Laurie Garrett wrote this week in Foreign Policy that even if this vaccine works as advertised, there are still plenty of reasons to worry about much good it can do. In this podcast extra, Garrett tells Brooke about what she views as caveats to the potential breakthrough. 

CORRECTION: This podcast contains an error concerning the timing of testing after the second dose of Pfizer's coronavirus vaccine candidate. According to a protocol released by Pfizer, Phase 3 study participants were tested for coronavirus "at least 7 days after receipt of the second dose," [emphasis added]. In this interview, Garrett says, "7 days after [the second dose], [participants] got a COVID test. The results presented are what was found at that seven-day point." Rather, the results announced by Pfizer earlier this month were based on testing conducted at least one week after the second dose. 

We reached out to Garrett for additional comment, and she added this: "All [Pfizer's] protocol required was a single test at the 7 day point. Eventually, Pfizer has extended that to 14 days. Since we don’t have any breakdown on numbers in the only published info — press release — we don’t know what % of the vax recipients were tested at 7 days, 8 days, 12 days…..no idea. So all we CAN say is that they all got a minimum of response time before testing. It’s a glass half full, half empty issue."

On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing [email protected].